Investigational Drug Study for Patients with Parkinson’s Disease-Related Constipation
Booth Gardner Parkinson’s Care Center is conducting a study to evaluate the safety, tolerability and effectiveness of repeated oral doses of an investigational drug for up to 25 days in patients with Parkinson’s Disease-related constipation.
Who may be eligible to participate?
Subjects 30-to-90 years of age with a diagnosis of Parkinson's Disease (defined as the presence of at least three of the following cardinal features: rest tremor, rigidity, bradykinesia and/or akinesia, postural and gait abnormalities) and constipation (which has been present for over 6 months and is unresponsive to first line, typically over the counter treatments).
Other inclusion/exclusion criteria apply.
What does participation involve?
The study will be conducted on an outpatient basis. Patients will be randomized 1:1 to treatment or placebo.
Each patient will have six visits to the clinic:
- a screening visit
- a randomization visit
- three follow up visits
- one end of study visit
Investigator
Daniel Burdick, MD, Booth Gardner Parkinson’s Care Center
